Unknown PHASE2 INTERVENTIONAL 1-arm NCT01625429

Neoadjuvant Study of Nab-paclitaxel Plus Carboplatin in Breast Cancer

A Single-center, Prospective, Phase II Study of Albumin-bound Paclitaxel (Nab-paclitaxel) and Carboplatin With or Without Trastuzumab (Herceptin) as Neoadjuvant Therapy in Locally Advanced Breast Cancer

Sponsor: Shanghai Cancer Hospital, China

Conditions Breast Cancer

Interventions nab-paclitaxel

Updated 6 times since 2017 Last updated: Nov 8, 2012 Started: Jun 30, 2012 Primary completion: Sep 30, 2013 Completion: Jun 30, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01625429, this PHASE2 trial focuses on Breast Cancer and remains ongoing. Sponsored by Shanghai Cancer Hospital, China, it has been updated 6 times since 2012, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2
Jul 2017 — Jun 2018 [monthly]

Unknown Status PHASE2

Status: Active Not Recruiting → Unknown Status

▶ Show 1 earlier version

Jan 2017 — Jul 2017 [monthly]

Active Not Recruiting PHASE2

First recorded

Jun 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shanghai Cancer Hospital, China

Data source: Shanghai Cancer Hospital, China

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China